Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965027 | 0.86 | ADORA3 (0.42) | ADORA3P2RX3NPC1NFKB1RAB9A | |
| SCHEMBL3958906 | 0.78 | ADORA2A (0.46) | ADORA3 | |
| SCHEMBL3955974 | 0.77 | ADORA3 (0.42) | ADORA3P2RX3 | |
| SCHEMBL3955978 | 0.77 | ADORA3 (0.44) | ADORA3P2RX3 | |
| SCHEMBL3961113 | 0.76 | PDE4A (0.49) | — | |
| SCHEMBL3955983 | 0.73 | PDE4A (0.41) | ADORA3 | |
| SCHEMBL22580552 | 0.73 | ADORA3 (0.51) | ADORA3P2RX3 | |
| SCHEMBL3959403 | 0.72 | PDE4A (0.47) | ADORA3 | |
| SCHEMBL3962765 | 0.71 | PIK3CD (0.41) | ADORA3 | |
| SCHEMBL3963204 | 0.71 | ADORA2A (0.52) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | claimed |
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |